NR1I2 and substance withdrawal syndrome: Hronova et al. investigated the influence of COMT and the human pregnant X receptor (PXR), in addition to ABCB1, on sufentanil and midazolam dosing, showing that these polymorphisms had an impact on dosing but did not affect the depth of analgo-sedation or the occurrence of withdrawal syndrome [87].